Isopogen is a public unlisted company developing life-changing cellular medicines.
Its patented StemSmart™ technology improves the clinical efficacy of Mesenchymal Stem Cells (MSC), offering a powerful competitive advantage against other MSC products.
Isopogen has received patent approval (expiring on 3 November 2034) for its StemSmart technology in Australia, the US, South Africa, Japan, Israel, and Singapore; and pending approval in Canada, China, Europe, Korea, Hong Kong and Brazil.
|
ADDED: Added to Technology Companies list | 23 Jan 2023 |
|
NEW ROLE: Rob McKenzie, Non-Executive Director | 15 Sep 2022 |
|
NEW ROLE: Paul Fry, Non-Executive Director | 15 Sep 2022 |
|
NEWS: Tagged in Isopogen fails to quash patent spat | 15 Sep 2022 |
|
NEWS: Tagged in State, Sturm in treatment tug-of-war | 28 Jul 2022 |
|
|
ADDED: Added to Technology Companies list | 16 Jan 2022 |
|
NEW ROLE: Marian Sturm, Chief Scientific Officer, Director | 16 Jan 2022 |
